Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewDimebon dihydrochloride
Discontinued Product
3201 has been discontinued.
Description: Neuroprotectant; protects against β-amyloid neurotoxicity
Alternative Names: Dimebone,Latrepirdine
Chemical Name: 2,3,4,5-Tetrahydro-2,8-dimethyl-5-[2-(6-methyl-3-pyridinyl)ethyl]-1H-pyrido[4,3-b]indole dihydrochloride
Purity: ≥98%
Biological Activity for Dimebon dihydrochloride
Non-selective antihistamine that displays cognitive enhancing abilities. Also displays high affinity for 5-HT (particularly 5-HT6 and 5-HT7), α-adrenergic, dopaminergic, AMPA and NMDA receptors, and L-type calcium channels. Does not inhibit acetylcholinesterase activity. Exhibits neuroprotective activity in cellular models of Alzheimer's and Huntington's disease and preserves cognitive function following administration to AF64A lesioned rats. Protects neurons against the neurotoxic action of β-amyloid fragment; shown to enhance autophagy in yeast and reduce intracellular Aβ42 levels.
Technical Data for Dimebon dihydrochloride
| M. Wt | 392.37 |
| Formula | C21H25N3.2HCl |
| Storage | Desiccate at RT |
| Purity | ≥98% |
| CAS Number | 97657-92-6 |
| PubChem ID | 23729232 |
| InChI Key | GTWLIQOLGOZTLF-UHFFFAOYSA-N |
| Smiles | CC(N=C4)=CC=C4CCN2C1=CC=C(C)C=C1C3=C2CCN(C)C3.Cl.Cl |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for Dimebon dihydrochloride
References for Dimebon dihydrochloride
References are publications that support the biological activity of the product.
Bachurin et al (2001) Antihistamine agent dimebon as a novel neuroprotector and a cognitive enhancer. Ann.N.Y.Acad.Sci. 939 425 PMID: 11462798
Schaffhauser et al (2009) Dimebon is a 5-HT6 antagonist with acute cognitive enhancing activities. Biochem.Pharmacol. 78 1035 PMID: 19549510
Okun et al (2009) From anti-allergic to anti-Alzheimer's: molecular pharmacology of dimebon. Curr.Alzheimer Res. 7 97
Giorgetti et al (2010) Cognition-enhancing properties of dimebon in a rat novel object recognition task are unlikely to be associated with acetylcholinesterase inhibition or N-MthD.-aspartate receptor antagonism J.Pharm.Exp.Ther. 333 748
Bharadwaj et al (2012) Latrepirdine (Dimebon) enhances autophagy and reduces intracellular GFP-Aβ42 levels in yeast. J.Alzheimers Dis. 32 949 PMID: 22903131
View Related Products by Target
Keywords: Dimebon dihydrochloride, Dimebon dihydrochloride supplier, cognitive, enhancer, alzheimers, huntingtons, disease, non-selective, antihistamine, neuroprotectant, neuroprotective, beta-amyloid, b-amyloid, β-amyloid, Huntington's, Latrepirdine, amyloidbeta, amyloidb, amyloidβ, Dimebone, Amyloid, Beta, Peptides, Histaminergic-Related, Compounds, 3201, Tocris Bioscience
Citations for Dimebon dihydrochloride
Citations are publications that use Tocris products.
Currently there are no citations for Dimebon dihydrochloride.
Reviews for Dimebon dihydrochloride
There are currently no reviews for this product. Be the first to review Dimebon dihydrochloride and earn rewards!
Have you used Dimebon dihydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's Disease Poster
Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.